Does PDMS really interact with [18F]fluoride? Applications in microfluidic reactors for 18F-radiopharmaceuticals
- 78 Downloads
Microfluidic devices used to synthesize radiopharmaceuticals for positron emission tomography (PET) are of increasing interest for the rapid preparation of on-demand doses, especially in medical centers that do not have a cyclotron. Polydimethylsiloxane (PDMS) is an inexpensive, easily available material used for the manufacturing of microfluidic devices. The literature often refers the interaction of this material with [18F]fluoride. Many authors discard PDMS as a suitable material because of these interactions, while others suggest the use of a thin fluoropolymer coating to reduce the adsorption of [18F]fluoride. The objective of this work was to evaluate the retention of [18F]fluoride within a PDMS reaction chamber without further treatment, under heating and vacuum in a range of activities that would allow to obtain enough product for two or three human doses of a radiopharmaceutical. Under these conditions, which are commonly used in radiosynthesis with [18F]fluoride, we found that [18F]fluoride was almost non-adsorbed into PDMS, making PDMS suitable for 18-F radiochemistry on single-use lab-on-chip devices, even uncoated.
KeywordsRadiopharmaceuticals Lab on chip PDMS Microfluidics Fluorine-18
The authors would like to acknowledge the support of Andalusian Government, project TIC 2296 “Microlab-en-chip para produccion de radiofarmacos para diagnostico PET”. Proyectos de Excelencia Junta de Andalucia, 2014, and the support of Siemens Healthineers and Curium Pharma.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Aerts J, Ballinger JR, Behe M, Decristoforo C, Elsinga P, Faivre-Chauvet A, Mindt TL, Peitl PK, Todde SC, Koziorowski J (2014) Guidance on current good radiopharmacy practice for the small scale preparation of radiopharmaceuticals using automated modules: a European perspective. J Label Compd Radiopharm 57:615–620CrossRefGoogle Scholar
- Arima V, Pascali G, Lade O, Kretschmer HR, Bernsdorf I, Hammond V, Watts P, De Leonardis F, Tarn MD, Pamme N, Cvetkovik BZ, Dittrich PS, Vasovic N, Duane R, Jaksic A, Zacheo A, Zizzari A, Marra A, Perrone E, Salvadori PA, Rinaldi R (2013) Radiochemistry on chip: towards dose-on-demand synthesis of PET radiopharmaceuticals. Lab Chip 13:2328–2336CrossRefGoogle Scholar
- Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Falvre-Chauvet A, Mikolajczak R, Westera G, Gmeiner-Stopar T, Decristoforo C (2010) Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 37:1049–1062CrossRefGoogle Scholar
- European Medicines Agency (2008) Eudralex. The rules Governing Medicinal Products in the European Union. Annex 3. Manufacture of RadiopharmaceuticalsGoogle Scholar
- Pharmaceutical Inspection Co-operation Scheme (PIC/s) (2019) Document PE 010-4Google Scholar
- Van Dam R, Elizarov AM, Ball CE, Kolb HC (2008) International patent WO2008/091694Google Scholar